Results 81 to 90 of about 3,235 (226)

Therapeutic potential of a Bax inhibitor‐1/TMBIM6 antagonist (BIA) and its analogues in Aspergillus fumigatus‐induced asthma via dual targeting of AKT and epithelial‐derived inflammatory cytokines

British Journal of Pharmacology, Volume 183, Issue 19, Page 5975-5991, October 2026.
Background and Purpose Aspergillus fumigatus (A. fumigatus) exposure causes of severe allergic asthma, characterized by airway inflammation and epithelial dysfunction. TMBIM6 (Bax inhibitor‐1) has been implicated in airway epithelial stress responses and AKT signalling.
Young‐Jin Yu, Ahsan Ullah, Jisun Kim, Mehedi Hasan Bappi, Yerim Heo, Jin Hee Ahn, Hyun‐Kyoung Kim, Han‐Jung Chae   +7 more
wiley   +1 more source

Tezepelumab for asthma with current or previous smoking habit: Case series

Journal of Allergy and Clinical Immunology: Global
Tezepelumab effectively treated severe asthma in a current smoker and a former smoker, suggesting that thymic stromal lymphopoietin is involved in the pathogenesis of severe asthma in these patients. Tezepelumab may additionally be used for severe asthma
Yoshiro Kai, MD, PhD, Kentaro Suzuki, MD, Ryosuke Kataoka, MD   +2 more
doaj   +1 more source

Updates in COPD Management: From Inflammatory Pathways to Targeted Therapies

European Journal of Clinical Investigation, Volume 56, Issue 10, October 2026.
COPD is a heterogeneous disease driven by overlapping neutrophilic and eosinophilic inflammatory pathways. This review highlights the shift from symptom‐based treatment toward phenotype‐ and biomarker‐directed care. Blood eosinophils, FeNO, and IgE predict corticosteroid responsiveness and identify candidates for biologic therapy.
Sasha Raman, Sreya Rahman, Francesca Polverino, Muhammad Adrish   +3 more
wiley   +1 more source

Extent of Sinus Surgery Is Associated With Disease Control in Biologic Treated Type 2 Dominant CRS

International Forum of Allergy &Rhinology, Volume 16, Issue 9, Page 986-995, September 2026.
ABSTRACT Background A greater benefit of biologics is observed after surgery in Type 2 chronic rhinosinusitis with nasal polyps (CRSwNP). However, the extent of surgery remains undefined in many studies. This study evaluated the extent of surgery on disease control in patients receiving biologics for refractory Type 2 dominant CRSwNP.
Nicholas J. Campion, Peta‐Lee Sacks, Lu Hui Png, Ruoxin Hua, Rhea Darbari Kaul, Raquel Alvarado, Christine Choy, Raymond Sacks, Peter Earls, Raewyn G. Campbell, Larry Kalish, Richard J. Harvey   +11 more
wiley   +1 more source

Real‐World Treatment Escalation Patterns of Biologics and Functional Endoscopic Sinus Surgery in Chronic Rhinosinusitis (CRS): A Nationwide Database Study

International Forum of Allergy &Rhinology, EarlyView.
Omer Baker, Bita Naimi, Soraya Mehdipour, Adam S. Deconde, Carol H. Yan   +4 more
wiley   +1 more source

Chronic Rhinosinusitis and Nasal Polyps in Eosinophilic Granulomatosis With Polyangiitis: A Scoping Review

International Forum of Allergy &Rhinology, Volume 16, Issue 9, Page 996-1011, September 2026.
ABSTRACT Background Chronic rhinosinusitis (CRS) is one of the most common manifestations of eosinophilic granulomatosis with polyangiitis (EGPA), often preceding the diagnosis of systemic vasculitis by several years. The sinonasal presentation of EGPA typically resembles CRS with nasal polyps (CRSwNP), making it clinically indistinguishable from those
Alisha Sharma, Alyssa Y. Li, Teruko Kishibe, Dennis Wong, Kevin M. Sanders, Maggie Jiang, Heedo Lee, Christine Song, Kieran Mcintyre, Christian Pagnoux, Yvonne Chan, John M. Lee, Daniel J. Lee   +12 more
wiley   +1 more source

Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies

, 2023
International audienceWhat is this summary about? This is a summary of the results of 2 clinical studies that looked at a medicine called tezepelumab.
Corren, Jonathan, Brightling, Christopher, Israel, Elliot, Menzies-Gow, Andrew, Griffiths, Janet, Wechsler, Michael, Almqvist, Gun, Bowen, Karin, Colice, Gene, Bourdin, Arnaud, Bimmel, Johan, Ponnarambil, Sandhia, Mcguinness, Anthony   +12 more
core   +1 more source

Tezepelumab: a promising therapy for severe uncontrolled asthma [PDF]

Exploration of Asthma & Allergy
Asthma is a complex inflammatory airway disease affecting a significant global population, spanning from childhood through adulthood. Despite advances in treatment modalities, a significant subset of patients, approximately 10%, grapple with severe ...
Argyri Klironomou, Georgia Papaiakovou, Agamemnon Bakakos, Nektarios Anagnostopoulos, Evangelia Koukaki, Efthymia Theofani, Maria Semitekolou, Nikoletta Rovina   +7 more
doaj   +1 more source

Effect of Tezepelumab on Sino-Nasal Outcome Test (SNOT)-22 Domain and Symptom-Specific Scores in Patients with Severe, Uncontrolled Asthma and a History of Chronic Rhinosinusitis with Nasal Polyps

Advances in Therapy
Tezepelumab blocks the activity of thymic stromal lymphopoietin, an epithelial cytokine implicated in the pathogenesis of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). In a previous analysis, tezepelumab improved asthma and rhinosinusitis
Joshua S. Jacobs, Joseph K. Han, J. Lee, T. M. Laidlaw, Nicole L. Martin, Scott Caveney, C. S. Ambrose, Neil Martin, J. Spahn, F. Hoyte   +9 more
semanticscholar   +1 more source

Phenotypic Clusters of Severe Asthma and Response to Dupilumab in Real‐World Practice

Clinical and Translational Allergy, Volume 16, Issue 9, September 2026.
ABSTRACT Background Severe asthma is a heterogeneous disease with variable clinical and inflammatory profiles that may influence responses to biological therapies. Identifying phenotypic clusters may help optimize patient selection and treatment outcomes.
Daria S. Fomina, Sergey V. Fedosenko, Аnton А. Chernov, Elena N. Bobrikova, Оlga А. Mukhina, Marina S. Lebedkina, Alexander V. Karaulov, Asel Yu. Nurtazina, Mariana A. Lysenko, Harald Renz   +9 more
wiley   +1 more source